Proactive Investors - Run By Investors For Investors

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".
Scientist using microscope
"With our new hires and recent funding, we believe we are in a strong position to progress our pipeline of immunotherapy products through the next stage of development"

Scancell Holdings PLC (LON:SCLP) said in its interim results that it has the cash to advance its pipeline of immunotherapy products.

The group ended the six month period to the end of October with a positive cash balance of £7.6mln, down from £10.3mln a year earlier.

READ: Scancell hires two industry veterans as it gears up for the next development phase

The pre-revenue company saw its loss before tax widen to £3.67mln from £2.39mln the year before.

Scancell's focus for the immediate future is to initiate the planned Phase 2 clinical study for its lead ImmunoBody, SCIB1, and to advance its lead Moditope vaccine, Modi-1, towards the clinic.

READ: Scancell licenses TriGrid electroporation device from Ichor Medical Systems

A positive outcome from both or either of these studies should represent significant value to shareholders, said John Chiplin, the company’s chairman.

READ: Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy 

"We are pleased to report another six months of progress at Scancell,” said Cliff Holloway, the chief executive officer of Scancell.

“We are working closely with Ichor and the FDA to provide the additional information requested for the initiation of our Phase 2 checkpoint inhibitor combination study of SCIB1 in patients with advanced melanoma,” he added.

 

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use